The pathogenesis of pulmonary fibrosis: A moving target

European Respiratory Journal

Volumn 41, Issue 5, 2013, Pages 1207-1218

  Wuyts, Wim A ^a,b   Agostini, Carlo ^c   Antoniou, Katerina M ^d   Bouros, Demosthenes ^e   Chambers, Rachel C ^f   Cottin, Vincent ^g   Egan, Jim J ^h   Lambrecht, Bart N ⁱ   Lories, Rik ^a   Parfrey, Helen ^j   Prasse, Antje ^k   Robalo Cordeiro, Carlos ^l   Verbeken, Eric ^b   Verschakelen, Johny A ^b   Wells, Athol U ^m   Verleden, Geert M ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF CRETE   (Greece)

^e DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITÉ LYON 1   (France)

^h UNIVERSITY COLLEGE DUBLIN   (Ireland)

ⁱ DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k UNIVERSITY OF FREIBURG   (Germany)

^l CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^m ROYAL BROMPTON HOSPITAL   (United Kingdom)

more..

Author keywords

Coagulation; Fibrosis; Immunology; Pathogenesis; Pulmonary fibrosis

Indexed keywords

CCL18 CHEMOKINE; CHEMOKINE; LYMPHOTOXIN; MACROPHAGE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CELL TYPE; CYTOKINE PRODUCTION; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ELMOD2 GENE; ENDOPLASMIC RETICULUM STRESS; EPSTEIN BARR VIRUS; FIBROSING ALVEOLITIS; GASTROESOPHAGEAL REFLUX; GENE FUNCTION; GENETIC PREDISPOSITION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMMUNE RESPONSE; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROSIS; LYMPH VESSEL; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS IDENTIFICATION; VIRUS INFECTION;

COAGULATION; FIBROSIS; IMMUNOLOGY; PATHOGENESIS; PULMONARY FIBROSIS;

ANIMALS; BLOOD COAGULATION; DISEASE PROGRESSION; ENDOPLASMIC RETICULUM STRESS; EPITHELIAL CELLS; GASTROESOPHAGEAL REFLUX; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MUTATION; OXIDATIVE STRESS; PULMONARY ALVEOLI; PULMONARY FIBROSIS; STEM CELLS;

EID: 84877097869     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00073012     Document Type: Review

References (111)

1. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980-985. (Pubitemid 44787169)
2. Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/ fibroblastic cross-talk disorder. Respir Res 2002; 3: 3.
3. Pulkkinen V, Bruce S, Rintahaka J, et al. ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses. FASEB J 2010; 24: 1167-1177.
4. Nogee LM, Dunbar AE, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344: 573-579. (Pubitemid 32167871)
5. Van Moorsel CHM, Van Oosterhout MFM, Barlo NP, et al. Surfactant protein C mutations are the basis of a significant portion of adult pulmonary fibrosis in a Dutch Cohort. Am J Respir Crit Care Med 2010; 182: 1419-1425.
6. Chibbar R, Shih F, Baga M, et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia with mutation in surfactant protein C in familial pulmonary fibrosis. Mod Pathol 2004; 17: 973-980. (Pubitemid 38993782)
7. Seibold MA, Wise AL, Speer MC, et al. A Common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364: 1503-1512.
8. Katzenstein ALA, Myers JL. Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301-1315.
9. Tang YW, Johnson JE, Browning PJ, et al. Herpes virus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol 2003; 41: 2633-2640. (Pubitemid 36712478)
10. Lung ML, Lam WK, So SY, et al. Evidence that respiratory tract is major reservoir for Epstein-Barr virus. Lancet 1985; 1: 889-892. (Pubitemid 15009180)
11. Egan JJ, Stewart JP, Hasleton PS, et al. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax 1995; 50: 1234-1239.
12. Stewart JP, Egan JJ, Ross AJ, et al. The detection of Epstein-Barr virus DNAin lung tissue frompatientswith idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1999; 159: 1336-1341. (Pubitemid 29202576)
13. Tsukamoto K, Hayakawa H, Sato A, et al. Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax 2000; 55: 958-961.
14. Sporn MB, Roberts AB. Transforming growth factor-β: recent progress and new challenges. J Cell Biol 1992; 119: 1017-1021.
15. Fukuda M, Ikuta K, Yanagihara K, et al. Effect of transforming growth factor-β1 on the cell growth and Epstein-Barr virus reactivation in EBV-infected epithelial cell lines. Virology 2001; 288: 109-118. (Pubitemid 32846479)
16. Pearson JE, Wilson RS. Diffuse pulmonary fibrosis and hiatus hernia. Thorax 1971; 26: 300-305.
17. Raghu G, Freudberger TD, Yang S, et al. High idiopathic pulmonary fibrosis. Eur Respir J 2006; 27: 136-142.
18. Sweet MP, Patti MG, Hoopes C, et al. Gastroeosophageal reflux and aspiration in patients with advanced lung disease. Thorax 2009; 64: 167-173.
19. Tcherakian C, Cottin V, Brillet PY, et al. Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax 2011; 66: 226-231.
20. Lee JS, Song JW, Wolters PJ, et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2012; 39: 352-358.
21. Kasper M, Haroske G. Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. Histol Histopathol 1996; 11: 463-483. (Pubitemid 26135211)
22. Thomas AQ, Lane K, Phillips J 3rd, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 12002, 65: 1322-1328.
23. Korfei M, Ruppert C, Mahavadi P, et al. Epithelial endopalmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178: 838-846.
24. Morishima Y, Nomura A, Uchida Y, et al. Triggering the induction of myofibroblast and fibrogenesis by airway epithelial shedding. Am J Respir Cell Mol Biol 2011; 24: 1-11.
25. Sisson TH, Mendez M, Choi K, et al. Targeted Injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care 2009; 164: 1605.
26. Selman M, Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006; 3: 364-372. (Pubitemid 43845414)
27. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 2007; 132: 1311-1321. (Pubitemid 47621009)
28. Willis BC, Borok Z. TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2007; 293: L525-L534. (Pubitemid 47358808)
29. Phillips RJ, Burdick MD, Hong K, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114: 438-446. (Pubitemid 39071616)
30. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 588-594.
31. Coward WR, Saini G, Jenkins G. The pathogenesisi of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2010; 4: 367-388.
32. Agostini C, Gurrieri C. Chemokine/cytokine cocktail in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3: 357-363. (Pubitemid 43845413)
33. Prasse A, Pechkovsky DV, Toews GB, et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 2006; 173: 781-792.
34. Zhang K, Gharaee-Kermani M, McGarry B, et al. TNF-α-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J Immunol 1997; 158: 954-959. (Pubitemid 127492676)
35. Miyazaki Y, Araki K, Vesin C, et al. Expression of a tumor necrosis factor-α transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest 1995; 96: 250-259.
36. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008; 178: 948-955.
37. Khalil N, Xu YD, O'Connor R, et al. Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. J Biol Chem 2005; 280: 43000-43009. (Pubitemid 43049264)
38. Ruiz V, Ordonez RM, Berumen J, et al. Unbalanced collagenases/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis. Am J Physiol Lung CellMol Physiol 2003; 285: L1026-L1036. (Pubitemid 37310092)
39. Zhang K, Gharaee-Kermani M, Jones ML, et al. Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis. J Immunol 1994; 153: 4733-4741.
40. Okuma T, Terasaki Y, Kaikita K, et al. C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. J Pathol 2004; 204: 594-604. (Pubitemid 39585959)
41. Gharaee-Kermani M, McCullumsmith RE, Charo IF, et al. CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. Cytokine 2003; 24: 266-276. (Pubitemid 37373662)
42. Selman M, Pardo A, Barrera L, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006; 173: 188-198. (Pubitemid 43187891)
43. Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002; 99: 6292-6297. (Pubitemid 34493305)
44. Dancer RCA, Wood AM, Thickett DR. Metalloproteinases in idiopathic pulmonary fibrosis. Eur Respir J 2011; 38: 1461-1467.
45. Selman M, Carrillo G, Estrada A, et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One 2007; 2: e482.
46. Konishi K, Gibson KF, Lindell KO, et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 180: 167-175.
47. Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981; 124: 1-8. (Pubitemid 11079332)
48. Watters LC, Schwarz MI, Cherniack RM, et al. Idiopathic pulmonary fibrosis. Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy. Am Rev Respir Dis 1987; 135: 696-704. (Pubitemid 17041608)
49. Katzenstein ALA, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis. Histological features and clinical significance. Am J Surg Pathol 1994; 18: 136-147. (Pubitemid 24046413)
50. Ryu YJ, Chung MP, Han J, et al. Bronchoalveolar lavage in fibrotic idiopathic interstitial pneumonias. Respir Med 2007; 101: 655-660. (Pubitemid 46196313)
51. Park CS, Jeon JW, Park SW. Nonspecific interstitial pneumonia/fibrosis: clinical manifestations, histologic and radiologic features. Korean J Intern Med 1996; 11: 122-132.
52. Nagai S, Kitaichi M, Itoh H, et al. Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur Respir J 1998; 12: 1010-1019. (Pubitemid 28545604)
53. Veeraraghavan S, Latsi PI, Wells AU, et al. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J 2003; 22: 239-244. (Pubitemid 36986991)
54. Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 1043-1047.
55. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 157: 199-203. (Pubitemid 28071283)
56. Daniil ZD, Gilchrist FC, Nicholson AG, et al. A histological pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1999; 160: 899-905. (Pubitemid 29442028)
57. Travis WD, Hunninghake G, King TE Jr, et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 2008; 177: 1338-1347. (Pubitemid 351860911)
58. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175: 705-711.
59. Song JW, Do KH, Kim MY, et al. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009; 136: 23-30.
60. Strange C, Highland KB. Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med 2004; 25, 549-559: vii.
61. Flaherty KR, Travis WD, Colby TV, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001; 164: 1722-1727. (Pubitemid 33124165)
62. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127: 2019-2027.
63. de Lauretis A, Veeraraghavan S, Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis 2011; 8: 53-82.
64. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010; 35: 1322-1328.
65. Hardie WD, Glasser SW, Hagood JS. Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol 2009; 175: 3-16.
66. Keane MP. The role of chemokines and cytokines in lung fibrosis. Eur Respir Rev 2008; 17: 151-156.
67. Strieter RM. Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest 2005; 128: Suppl. 1, 526S-532S.
68. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345: 517-525. (Pubitemid 32758505)
69. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13: 139-145.
70. Yogo Y, Fujishima S, Inoue T, et al. Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis. Respir Res 2009; 10: 80.
71. Belperio JA, Dy M, Murray L, et al. The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J Immunol 2004; 173: 4692-4698. (Pubitemid 39280704)
72. Prasse A, Probst C, Bargagli E, et al. Serum CC-Chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 717-723.
73. Joshi AD, Fong DJ, Oak SR, et al. Interleukin-17-mediated immunopathogenesis in experimental hypersensitivity pneumonitis. Am J Respir Crit Care Med 2009; 179: 705-716.
74. Belghith M, Bluestone JA, Barriot S, et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9: 1202-1208. (Pubitemid 37173706)
75. Lambeth JD. Nox enzymes, ROS and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 2007; 43: 332-347. (Pubitemid 46992767)
76. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation or fibrotic disease. Nat Med 2012; 18: 1029-1040.
77. Wang E. Senescent human fibroblasts resit programmed cell death and failure to suppress bcl2 is involved. Cancer Res 1995; 55: 2284-2292.
78. Waghray M, Cui Z, Horowitz JC, et al. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J 2005; 19: 854-856. (Pubitemid 40617407)
79. Takemasa A, Ishii Y, Fukuda TA. Neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice. Eur Respir J 2012; 40: 1475-1482.
80. Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989; 139: 370-372. (Pubitemid 19057410)
81. Demedts M, Behr J, Buhl R, et al. High-dose N-acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353: 2229-2242. (Pubitemid 41697286)
82. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977.
83. Wells AU, Behr J, Costabel U, et al. Triple therapy in idiopathic pulmonary fibrosis: an alarming press release. Eur Respir J 2012; 39: 805-806.
84. Schroder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005; 74: 739-789. (Pubitemid 40995523)
85. Lawson WE, Crossno PF, Polosukhin VV, et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpes virus infection. Am J Physiol Lung Cell Mol Physiol 2008; 294: L1119-L1126.
86. Tanjore H, Cheng DS, Degryse AL, et al. Alveolar epithelial cells undergo epithelial-to mesenchymal transition in response to endoplasmic reticulum stress. J Biol Chem 2001; 286: 30972-30980.
87. Mahavadi P, Korfei M, Henneke I, et al. Epithelial stress and aopotosis underlie Hermansky-Pudlak syndrome-associated interstitial pneumonia. Am J Respir Crit Care Med 2010; 182: 207-219.
88. Chambers RC, Leoni P, Blanc-Brude OP, et al. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J Biol Chem 2000; 275: 35584-35591.
89. Jenkins RG, Su X, Su G, et al. Ligation of protease-activated receptor 1 enhances a(v)b6 integrin-dependent TGF-α activation and promotes acute lung injury. J Clin Invest 2006; 116: 1606-1614.
90. Mercer PF, Johns RH, Scotton CJ, et al. Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 414-425.
91. Blanc-Brude OP, Archer F, Leoni P, et al. Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation. Exp Cell Res 2005; 304: 16-27. (Pubitemid 40222073)
92. Chambers RC, Dabbagh K, McAnulty RJ, et al. Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. Biochem J 1998; 333: 121-127. (Pubitemid 28342501)
93. Bogatkevich GS, Tourkina E, Silver RM, et al. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem 2001; 276: 45184-45192.
94. Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol 2008; 153: Suppl. 1, S367-S378. (Pubitemid 351340998)
95. Howell DC, Johns RH, Lasky JA, et al. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 2005; 166: 1353-1365. (Pubitemid 40586507)
96. Scotton CJ, Krupiczojc MA, Königshoff M, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009; 119: 2550-2563.
97. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 88-95.
98. Capodanno D, Bhatt DL, Goto S, et al. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. J Thromb Haemost 2012; 10: 2006-2015.
99. Pusztazeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor and Fli-1 in normal human tissues. J Histochem Cytochem 2006; 54: 385-395.
100. Yamashita M, Iwama N, Date F, et al. Characterization of lymphangiogenesis in various stages of idiopathic diffuse alveolar damage. Hum Pathol 2009; 40: 542-551.
101. Sozio F, Rossi A, Weber E, et al. Morphomtric analysis of intralobular, interlobular and pleural lymphatics in normal human lung. J Anat 2012; 220: 396-404.
102. Marchetti C, Poggi P, Clement MG, et al. Lymphatic capillaries of the pig lung: TEM and SEM observations. Anat Rec 1994; 238: 368-373. (Pubitemid 24079440)
103. Hainis KD, Sznajder JI, Schraufnagel DE. Lung lymphatics cast from the airspace. Am J Physiol 1994; 267: L199-L205. (Pubitemid 24258844)
104. Souza CA, Muller NL, Lee KS, et al. Idiopathic interstitial pneumonias: prevalence of mediastinal lymph node enlargement in 206 patients. Am J Roentgenol 2006; 186: 995-999. (Pubitemid 46100198)
105. Teles-Grilo ML, Leite-Almeida H, Martins dos Santos J, et al. Differential expression of collagens type I and type IV in lymphangiogenesis during the angiogenic process associated with bleomycin induced pulmonary fibrosis in rat. Lymphology 2005; 38: 130-135. (Pubitemid 41609629)
106. El-Chemaly S, Malide D, Zudaire E, et al. Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms. Proc Natl Acad Sci USA 2009; 106: 3958-3963.
107. Ebina M, Shibata N, Ohta H, et al. The disappearance of subpleural and interlobular lymphatics in IPF. Lymphat Res Biol 2010; 8: 199-207.
108. Sueblinvong V, Loi R, Eisenhauer PL, et al. Derivation of lung epithelium from human cord blood-derived mesenchymal stem cells. Am J Respir Crit Care Med 2008; 177: 701-711. (Pubitemid 351490557)
109. Wang D, Haviland DL, Burns AR, et al. A pure population of lung alveolar epithelial type II cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 2007; 104: 4449-4454. (Pubitemid 47186246)
110. Spitalieri P, Quitadamo MC, Orlandi A, et al. Rescue of murine silica-induced lung injury and fibrosis by human embryonic stem cells. Eur Respir J 2012; 39: 446-457.
111. Ortiz LA, Gambelli F, McBride CS. Mesenchymal stem cells engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003; 100: 8407-8411. (Pubitemid 36842558)